Bv8 regula la angiogénesis tumoral dependiente de las células mieloides
Farbod Shojaei1, Xiumin Wu, Cuiling Zhong
1Genentech Inc., 1 DNA Way, South San Francisco, California 94080, USA.
Nature
|December 8, 2007
Resumen
Prokineticin-2 (Bv8) moviliza las células mieloides de la médula ósea para promover la angiogénesis tumoral. El bloqueo de Bv8 con anticuerpos inhibe el crecimiento tumoral y la angiogénesis, ofreciendo una estrategia terapéutica potencial.
Área de la Ciencia:
- Oncología Oncología.
- Inmunología Inmunología.
- Biología Molecular Biología Molecular
Sus antecedentes:
- Las células derivadas de la médula ósea son cruciales para la angiogénesis tumoral, pero los mecanismos siguen sin estar claros.
- Las prokineticinas, incluida la Bv8 (prokineticina 2), regulan la angiogénesis y la movilización de las células hematopoyéticas.
- Bv8 se expresa en la médula ósea, lo que sugiere un papel en la movilización de células mieloides asociadas al tumor.
Objetivo del estudio:
- Para aclarar el papel de Bv8 en la angiogénesis tumoral y la movilización de células mieloides.
- Para investigar la regulación de la expresión de Bv8 en las células mieloides.
- Evaluar el potencial terapéutico de los anticuerpos anti-Bv8 en modelos de cáncer.
Principales métodos:
- Implantación de tumores en ratones para estudiar la expresión de Bv8 en las células mieloides (CD11b+Gr1+).
- Identificación del factor estimulante de las colonias de granulocitos como regulador de Bv8.8.
- Administración de anticuerpos anti-Bv8 y administración de Bv8 adenoviral in vivo.
- Evaluación del crecimiento tumoral, la angiogénesis y las poblaciones de células mieloides.
Principales resultados:
- Implantación de células tumorales Bv8 regulado al alza en células mieloides, regulado por el factor estimulante de colonias de granulocitos.
- Los anticuerpos anti-Bv8 inhiben la movilización de las células mieloides y la angiogénesis tumoral.
- La administración de adenovirus Bv8 promovió la angiogénesis dentro de los tumores.
- El tratamiento anti-Bv8 suprimió el crecimiento tumoral, la angiogénesis y la infiltración de células mieloides, con efectos aditivos al anti-VEGF o la quimioterapia.
Conclusiones:
- Bv8 juega un doble papel en el cáncer al modular la movilización de células mieloides de la médula ósea y promover la angiogénesis tumoral local.
- Dirigirse a Bv8 representa una estrategia terapéutica prometedora para inhibir el crecimiento tumoral y la angiogénesis.
Más Videos Relacionados
Videos de Conceptos Relacionados
Regulation of Angiogenesis and Blood Supply
3.1K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.1K
Mechanism of Angiogenesis
6.3K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.3K
Regulation of Hematopoietic Stem Cells
3.7K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.7K
Receptor Downregulation in MVBs
2.6K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.6K
mTOR Signaling and Cancer Progression
4.2K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.2K
Differentiation of Common Myeloid Progenitor Cells
3.7K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.7K


